Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked 4-hydroxyestrdiol diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. positive controls Cisplatin and doxorubicin against other malignancy’ cell lines ad... by MohammedBashar Al-Qazzan (22439236)

Subjects:

The role of glyoxalase system in methylglyoxal detoxification. by MohammedBashar Al-Qazzan (22439236)

Subjects:

IC₅₀ values (mean ±SD in μM) of <i><i>in vitro</i></i> DPPH-radical scavenging properties vs. ascorbic acid and antiinflammation propensities vs. indomethacin of the tes... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Shikonin diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Active compounds identified as glyoxalase-I inhibitors. by MohammedBashar Al-Qazzan (22439236)

Subjects:

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Subjects:

3D and 2D pose of the docked Tolcapone diagram displaying a variety of interactions with enzyme’s active region. by MohammedBashar Al-Qazzan (22439236)

Subjects:

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

Subjects:

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

Subjects:

Open data. by Larissa Brazolotto Ferreira (17671168)

Subjects:

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Subjects:

Mapping of transposon insertions in the selected mutants of <i>M</i>. <i>bovis</i> PG45. by Aga E. Gelgie (17661720)

Subjects:

S1 Data - by Hao Deng (409186)

Subjects:

Change in the genotypes of <i>ATM</i>, <i>ERCC1</i>, and <i>XRCC1</i>. by Hao Deng (409186)

Subjects: